LAVAL, QC, March 17 /CNW/ - BioSyntech, Inc. ("BioSyntech" or "the
Company") (TSX: BSY), a biotechnology company developing novel products in
regenerative medicine, today announced it has received positive preliminary
results from a prospectively planned six-month interim analysis of its
Canadian-European pivotal clinical trial for BST-CarGel(R). Results drawn from
a 20 subject subset of the trial indicate evidence of a positive effect of
BST-CarGel(R) treatment on cartilage structure when compared to the surgical
control. The interim analysis also showed the safety of BST-CarGel(R) to be
comparable to the control. The sole purpose of this interim analysis was to
obtain pilot data for submission to the U.S. Food and Drug Administration
(FDA) as a pilot study in support of an Investigational Device Exemption (IDE)
for a U.S. pivotal trial for this medical device.
